Amarin petitions Supreme Court to revive Vascepa patents
18-02-2021
Ruling opens door for Noven’s oestrogen patch generics
10-09-2020
FDA approves Dr Reddy’s Vascepa generic
13-08-2020
Pavel Kapysh / Shutterstock.com
Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa (icosapent ethyl).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amarin, Vascepa, en banc, Federal Circuit, heart medicine, invalidated patents, FDA, generics, Hikma, remedies, appeal, global market, healthcare
